4-(1H-Indol-4-yl)-N-phenylpiperazine-1-carboxamide

Catalog No. :
ACZKUG327
CAS No. :
882256-55-5
Molecular Formula :
C19H20N4O
Molecular Weight :
320.40

IUPAC Name:iGOT1-01

4-(1H-Indol-4-yl)-N-phenylpiperazine-1-carboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$159.00Login to see priceInquiryInquiry
10mg98%$236.00Login to see priceInquiryInquiry
25mg98%$428.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(1H-Indol-4-yl)-N-phenylpiperazine-1-carboxamide
IUPAC NameiGOT1-01
Molecular FormulaC19H20N4O
Molecular Weight320.40
SMILESO=C(N1CCN(C2=CC=CC3=C2C=CN3)CC1)NC4=CC=CC=C4
InChI KeyMGSDOEMLWKEWSV-UHFFFAOYSA-N
SynonymiGOT1-01;1-Piperazinecarboxamide, 4-(1H-indol-4-yl)-N-phenyl-;iGOT1-01,GLOX,aspartate,Inhibitor,anti-cancer,transaminase,inhibit,iGOT1 01,GOT1,HRP,aminotransferase,glutamate,iGOT101,MDH,oxaloacetate;iGOT1-01, 10 mM in DMSO;4-?(1H-?Indol-?4-?yl)?-?N-?phenyl-1-?piperazinecarboxamid?e
CAS No.882256-55-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACZKUG327 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZKUG327 route product structure diagram
    ACZKUG327882256-55-5
Inquiry

2. ACZKUG327 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZKUG327 route product structure diagram
    ACZKUG327882256-55-5
Inquiry

Comments (0)